Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DURAPHYL vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronchodilator via beta-2 adrenergic receptor agonism; increases c AMP, relaxes bronchial smooth muscle.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Maintenance treatment of asthma,Bronchospasm associated with COPD
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life is 7–9 hours in adults with normal hepatic function; prolonged to 20–30 hours in hepatic cirrhosis or heart failure. In neonates, half-life may exceed 30 hours due to immature CYP450 enzymes.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP450 (CYP2D6, CYP3A4) and catechol-O-methyltransferase (COMT).
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites. Less than 10% excreted unchanged in urine; approximately 70% recovered in urine as metabolites, 30% in feces.
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.45–0.50 L/kg, approximating total body water. Higher Vd (0.6–0.7 L/kg) in premature neonates and patients with hepatic cirrhosis due to reduced protein binding.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 96–100%; oral extended-release: 90–100%; rectal: 80–90%; intramuscular: 100% (but not recommended due to erratic absorption).
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50% and administer once daily. GFR <15 m L/min: contraindicated.
No data; not applicable.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and administer once daily. Child-Pugh Class C: contraindicated.
No data; not applicable.
Children ≥12 years: initiate at 2.5 mg orally twice daily, increase to 5 mg twice daily after one week; maximum 10 mg twice daily. Children 6–11 years: 1.25 mg orally twice daily, increase to 2.5 mg twice daily after one week; maximum 5 mg twice daily. Children <6 years: not established.
No data; not applicable.
Initiate at 2.5 mg orally twice daily, increase to 5 mg twice daily after one week; maximum 10 mg twice daily. Monitor renal function and adjust per renal dosing.
No data; not applicable.
No FDA boxed warning.
None
Paradoxical bronchospasm,Cardiovascular effects (tachycardia, arrhythmia, hypertension),Hypokalemia,Hyperglycemia,Immediate hypersensitivity reactions
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to active ingredient or excipients,Cardiac arrhythmias (especially tachyarrhythmias)
Hypersensitivity to arformoterol or any component of the formulation
Avoid high-fat meals which may slow absorption. Avoid charcoal-broiled foods which can decrease effectiveness. Limit caffeine intake. Grapefruit juice may increase absorption; avoid excessive consumption.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
DURAPHYL (theophylline) is not associated with major congenital malformations in humans; however, third-trimester use may cause transient neonatal tachycardia, irritability, and jitteriness due to transplacental passage. Limited data suggest no increased risk of first-trimester major defects after therapeutic doses, but high doses near term may lead to caffeine-like withdrawal in neonates.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with an estimated M/P ratio of 0.6–0.7. Infant serum levels may reach 10–50% of maternal therapeutic concentrations. Irritability and sleep disturbance have been reported in breastfed infants. Benefit-risk assessment indicates cautious use; consider monitoring infant for signs of theophylline toxicity.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Theophylline clearance may decrease by 20–40% in the third trimester due to reduced hepatic metabolism. Dose reduction of 20–30% is often required to maintain therapeutic levels. Frequent serum concentration monitoring is advised every 2–4 weeks in the third trimester and postpartum, as clearance normalizes within 1–2 weeks, requiring upward dose adjustment.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Duraphyl (theophylline) has a narrow therapeutic index; monitor serum levels to maintain 10-20 mcg/m L. Avoid in patients with seizure disorders unless adequately controlled. Cimetidine, ciprofloxacin, and macrolides increase levels; rifampin and phenytoin decrease levels. Use with caution in hepatic impairment and congestive heart failure.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heartbeat, seizures, or insomnia.,Do not stop suddenly; tapering may be needed to prevent worsening of breathing problems.,Inform your doctor if you start or stop smoking, as smoking affects theophylline levels.,Keep a regular schedule; take at the same times each day with a full glass of water.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DURAPHYL vs AEROLONE, answered by our medical review team.
DURAPHYL is a Bronchodilator that works by Bronchodilator via beta-2 adrenergic receptor agonism; increases c AMP, relaxes bronchial smooth muscle.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DURAPHYL and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DURAPHYL is: 5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DURAPHYL and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DURAPHYL is classified as Category C. DURAPHYL (theophylline) is not associated with major congenital malformations in humans; however, third-trimester use may cause transient neonatal tachycardia, irritability, and ji. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.